A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism.
PATTERNS (NEW YORK, N.Y.) 2022;
3:100433. [PMID:
35510183 PMCID:
PMC9058900 DOI:
10.1016/j.patter.2021.100433]
[Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 08/30/2021] [Accepted: 12/23/2021] [Indexed: 01/04/2023]
Abstract
The high number of failed pre-clinical and clinical studies for compounds targeting Alzheimer disease (AD) has demonstrated that there is a need to reassess existing strategies. Here, we pursue a holistic, mechanism-centric drug repurposing approach combining computational analytics and experimental screening data. Based on this integrative workflow, we identified 77 druggable modifiers of tau phosphorylation (pTau). One of the upstream modulators of pTau, HDAC6, was screened with 5,632 drugs in a tau-specific assay, resulting in the identification of 20 repurposing candidates. Four compounds and their known targets were found to have a link to AD-specific genes. Our approach can be applied to a variety of AD-associated pathophysiological mechanisms to identify more repurposing candidates.
Drug-repurposing approach that combines in silico analyses and in vitro screenings
A drug- and mechanism-oriented model, the Human Brain Pharmacome (HBP) was created
The HBP was used to mine data related to drugs and targets to generate a hypothesis
Experimental evidence validated predicted drug-target combinations
Owing to current setbacks in the discovery and development of novel treatments tackling Alzheimer disease (AD), a re-evaluation of research and development (R&D) strategies is underway. Here, we present a holistic pharmacological approach that combines drug-target information with knowledge graphs that represent essential pathophysiology mechanisms. The resulting Human Brain Pharmacome (HBP) embeds hundreds of relevant drug-target interactions in the context of disease mechanisms governing AD. We demonstrate how such a tool can be used to aid AD research by identifying already-approved drugs that have the potential to treat the disease, thereby bypassing the expensive and time-consuming task of researching and developing a new drug. In our study, we identified new drug-target combinations and provided mechanistic explanations that help to improve our understanding of AD pathology and support future development of effective therapeutic strategies.
Collapse